Oncology Institute Inc. (STLN)
Oncology Institute Inc. (STLN) Stock Price, Analysis & Data
| Bid | 6.25 |
| Market Cap | 644.11M |
| Revenue (ttm) | 587.24M |
| Net Income (ttm) | -30.56M |
| Beta | 0.42 |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -38.77 |
| P/S (ttm) | 1.10 |
| Earnings Date | Nov 9, 2026 |
| Ask | 7.25 |
| Volume | 1,277,570 |
| Avg. Volume (20D) | 1,950,459 |
| Open | 6.14 |
| Previous Close | 6.20 |
| Day's Range | 5.99 - 6.37 |
| 52-Week Range | 2.32 - 7.05 |
| Analyst | Strong Buy |
| Price Target | 9 (42.41%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About STLN
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, ...
Financial Performance
In 2025, Oncology Institute's revenue was 502.73M, an increase of 27.79% compared to the previous year's 393.41M. Earnings were -60.61M, a decrease of -6.27%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for STLN stock is "Strong Buy". The 12-month stock price forecast is 9, which is upside of 42.41% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
